The Hidden Cost of Chronic Conditions in Today’s Workforce

Healthcare costs continue to rise but for many employers, the financial impact of chronic conditions extends far beyond medical claims and pharmacy spending. Research has found that chronic conditions are associated with increased absenteeism, lower workplace productivity, disability-related costs, and broader workforce challenges that can affect organizational performance, according to the CDC's Preventing Chronic Disease journal.

As chronic conditions become increasingly common among working-age adults, employers are beginning to understand that workforce health is not simply a benefits issue, but it’s become a business issue.

According to the Centers for Disease Control and Prevention (CDC), six in ten U.S. adults live with at least one chronic disease, while four in ten live with two or more. Conditions such as heart disease, diabetes, obesity, and hypertension are no longer affecting a small subset of the population but instead have become a defining characteristic of the modern workforce.

This reality carries significant implications for employers, particularly as organizations continue to face rising healthcare expenditures and increased pressure to improve workforce performance.

‍

The Cost of Chronic Disease Extends Beyond Healthcare Spending

When employers think about chronic conditions, healthcare costs are often the first concern. The financial impact is substantial. The CDC estimates that 90% of the nation's annual healthcare expenditures are associated with people living with chronic and mental health conditions.

For employer-sponsored health plans, those costs continue to climb. The latest KFF Employer Health Benefits Survey found that average annual premiums for family coverage reached nearly $27,000 in 2025, continuing a long-term trend that has challenged benefits budgets across industries.

Yet medical spending represents only part of the financial burden. Chronic conditions can affect an employee's ability to consistently perform at their highest level. Ongoing health challenges may contribute to more missed workdays, increased medical appointments, periods of disability leave, and reduced productivity while employees are on the job. These indirect costs are often difficult to quantify, but they can significantly influence overall business performance.

Research published in the CDC's Preventing Chronic Disease journal found that chronic health conditions are associated with both absenteeism and lower workplace productivity. For employers, the cumulative impact can be substantial, particularly when large portions of the workforce are managing one or more chronic conditions.

‍

‍

Why Employers Are Paying Attention

The growing prevalence of chronic disease is reshaping conversations around workforce health. According to the Business Group on Health 2025 Employer Health Care Strategy Survey, employers continue to rank healthcare costs among their top concerns while placing greater emphasis on strategies that support employee health and wellbeing. This growing focus on workforce health has also contributed to increased employer interest in emerging chronic disease management strategies, including GLP-1 medications for eligible individuals living with obesity and related conditions. This shift reflects a broader recognition that workforce health influences far more than healthcare spending. It can affect productivity, employee engagement, retention, and overall organizational performance.

In many ways, chronic conditions represent a challenge that extends across multiple business functions. Human resources teams, benefits leaders, finance departments, and executive leadership all have a stake in understanding how employee health influences organizational outcomes.

‍

The Prevention Gap

Despite growing awareness of chronic disease, prevention remains one of healthcare's most persistent challenges. Many chronic conditions develop gradually over time and are influenced by a complex combination of lifestyle, environmental, genetic, and socioeconomic factors. While healthcare access plays an important role, access alone does not guarantee engagement with preventive care or sustained health management.

As a result, much of the healthcare system remains focused on managing conditions after they emerge rather than preventing them before they develop. As employers respond to the growing impact of chronic disease, many are evaluating programs that combine evidence-based treatment with ongoing support for people living with chronic conditions. The eMed GLP-1 program combines FDA-approved medication, when clinically appropriate, with continuous clinical support as part of a comprehensive approach to chronic disease management.

As workforce health challenges continue to influence healthcare costs and organizational performance, employers are increasingly recognizing the value of comprehensive care models that support employees throughout their treatment journey. While medical innovation continues to advance, the underlying burden of chronic disease remains widespread.

‍

‍

‍

Where GLP-1 Programs Enter the Conversation

As employers look for ways to address the growing burden of chronic conditions, GLP-1 medications have become an increasingly important topic in workforce health discussions.

Originally developed to treat type 2 diabetes, newer GLP-1 therapies are also approved for chronic weight management in eligible patients. Their emergence has prompted many employers to reevaluate how obesity fits within broader chronic disease strategies, particularly given the well-established relationship between obesity and conditions such as type 2 diabetes, hypertension, cardiovascular disease, and sleep apnea.

The conversation is being driven, in part, by the scale of the challenge. According to the CDC Adult Obesity Facts, more than 40% of U.S. adults live with obesity, a condition associated with increased risk for numerous chronic diseases. As obesity prevalence has risen, employers have faced growing healthcare expenditures tied to obesity-related conditions and their downstream complications.

At the same time, GLP-1 medications have introduced new considerations for employer-sponsored health plans. The Business Group on Health 2025 Employer Health Care Strategy Survey found that employer coverage of GLP-1 medications for weight management continues to expand, reflecting increased interest in addressing obesity as part of a broader population health strategy. However, these therapies can also represent a significant pharmacy investment, prompting employers to carefully evaluate how to balance access, affordability, and long-term health outcomes.

This has shifted the conversation beyond medication alone. Many organizations are exploring comprehensive approaches that combine clinical oversight, lifestyle support, ongoing engagement, and evidence-based treatment pathways to help employees manage chronic conditions more effectively. Increasingly, employers are evaluating GLP-1 programs within the context of broader chronic disease management initiatives rather than as standalone pharmacy benefits. The eMed GLP-1 program reflects this broader approach by pairing FDA-approved medication, when clinically appropriate, with ongoing clinical care and accountability designed to support eligible employees throughout treatment.

As chronic disease continues to influence healthcare costs, productivity, and workforce performance, GLP-1 programs have become part of a larger discussion about how employers can support employee health while managing the long-term financial impact of chronic conditions.

‍

Looking Ahead

The conversation around chronic disease is often framed as a healthcare issue but is also becoming a workforce and business issue.

As organizations navigate rising healthcare costs, evolving workforce expectations, and ongoing productivity challenges, understanding the full impact of chronic conditions will become even more important. Healthcare claims tell part of the story. The broader effects on productivity, absenteeism, employee experience, and organizational performance tell the rest.

For employers seeking to build resilient, high-performing workforces, chronic conditions are no longer a challenge that can be viewed solely through the lens of healthcare spending, they are a factor that influences the health of both employees and the organizations they help power.

Chronic conditions are reshaping workforce health and employer healthcare costs. See how the eMed GLP-1 program helps employers support eligible employees as part of a broader chronic disease management strategy. Learn more

‍

_{Disclaimer: This blog is maintained by eMed for informational purposes only. Content published here does not constitute medical, legal, financial, or benefits advice and should not be relied upon as such. Third-party statistics, studies, and research cited are sourced from publicly available data and provided for general informational context only; eMed makes no representation as to their accuracy, completeness, or applicability to any specific employer population, and results may vary. eMed's GLP-1 program pairs FDA-approved, on-label medications with clinical oversight; individual health outcomes depend on a variety of clinical and personal factors and cannot be guaranteed.}

_{Any content authored or posted by eMed employees reflects their personal opinions and perspectives only and does not represent the views, positions, or official statements of eMed or its affiliates.}

‍